Patents Assigned to Merck Sharp & Dohme LLC
-
Publication number: 20230288140Abstract: A microwave vacuum dryer includes a loading chamber and a first vacuum pump in communication with the loading chamber, a first door separating the loading chamber from an external environment, a drying chamber adjacent the loading chamber, a second vacuum pump in communication with the drying chamber, and a condenser in communication with the drying chamber, a second door separating the loading chamber and the drying chamber, an unloading chamber adjacent the drying chamber and a third vacuum pump in communication with the unloading chamber, a third door separating the drying chamber from the unloading chamber, a fourth door separating the unloading chamber from the external environment, and a microwave chamber having a plurality of magnetrons, the microwave chamber positioned on a different plane from the loading and unloading chambers and adjacent the drying chamber.Type: ApplicationFiled: June 1, 2021Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Akhilesh BHAMBHANI, Jeffrey T. BLUE, Robert K. EVANS, Terrence FENNELL, Justin STANBRO
-
Publication number: 20230287141Abstract: Antibodies that bind the apple 3 domain of human coagulation Factor XI and inhibit activation of FXI by coagulation factor XIIa as well as activation of FIX by FXIa are described.Type: ApplicationFiled: April 18, 2023Publication date: September 14, 2023Applicants: Merck Sharp & Dohme LLC, Adimab, LLCInventors: Zhu Chen, Kenneth Ellsworth, James Milligan, Elizabeth Oldham, Dietmar Seiffert, Bianka Prinz, Vaishnavi Ganti, Mohammad Tabrizifard
-
Publication number: 20230287032Abstract: The present invention relates to efficient processes useful in the preparation of fluorinated nucleosides, such as (O—{[(2R,3R,4S,5R)-5-(6-amino-9H-purin-9-yl)-4-fluoro-3-hydroxyoxolan-2-yl]methyl}O,O-dihydrogen phosphorothioate, also known as 2?-(S)-fluoro-thio-adenosine monophosphate or 2?-F-thio-AMP. Such fluorinated nucleosides may be useful as a biologically active compound and or as an intermediate for the synthesis of more complex biologically active compounds. The present invention also encompasses intermediates useful in the disclosed synthetic processes and the methods of their preparation.Type: ApplicationFiled: August 11, 2021Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Cheol Keun Chung, Zhijian Liu, Peter E. Maligres, Edna Mao, Jennifer V. Obligacion, Eric M. Phillips, Michael Pirnot, Marc Poirier, Zhiguo Jake Song, Tao Wang
-
Publication number: 20230286958Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.Type: ApplicationFiled: June 10, 2021Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Salman Jabri, Anthony Ken Ogawa, Christopher J. Sinz, Jacqueline D. Hicks, Alan C. Cheng, Ying-Duo Gao, Song Yang, Jianming Bao, Donna A. A. W. Hayes, Simon B. Lang, Brandon M. Taoka, Maoqun Tian, Galen Paul Shearn-Nance, Rongze Kuang, Matthew J. Lombardo, Zhicai Wu, Zhiqiang Zhao
-
Publication number: 20230285514Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: ApplicationFiled: December 18, 2020Publication date: September 14, 2023Applicant: Merck Sharp & Dohme LLCInventors: Elisabetta Bianchi, Paul E. Carrington, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
-
Publication number: 20230277644Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. In some embodiments, at least one of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. In further embodiments, each of the polysaccharide protein conjugates is formed by a conjugation reaction comprising an aprotic solvent. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae.Type: ApplicationFiled: March 23, 2023Publication date: September 7, 2023Applicant: Merck Sharp & Dohme LLCInventors: Chitrananda Abeygunawardana, Yadong Adam Cui, Romulo Ferrero, Jian He, Luwy Musey, Tanaz Petigara, Julie M. Skinner
-
Publication number: 20230277654Abstract: The present invention relates to stable formulations of a cytomegalovirus (CMV) comprising for example, a genetically modified CMV that is conditionally replication defective, a buffer, alkali or alkaline salt, a sugar, a cellulose derivative and optionally a polyol.Type: ApplicationFiled: November 30, 2022Publication date: September 7, 2023Applicant: Merck Sharp & Dohme LLCInventors: Muneeswara Babu Medi, Harrison Bradford Davis, Lorenzo H. Chen, Lynne Ann Isopi, Jeffrey Thomas Blue, Heidi Joanne Pixley, Erin J. Green-Trexler
-
Publication number: 20230277779Abstract: An injecting device includes a reservoir for containing a medicament, a needle in communication with the reservoir and configured to deliver the medicament to a patient’s body, at least two electrodes spaced apart from one another and disposed on opposing sides of the needle, and a capacitance-to-digital converter circuit configured to generate a signal and measure capacitance between the at least two electrodes.Type: ApplicationFiled: May 15, 2023Publication date: September 7, 2023Applicant: Merck Sharp & Dohme LLCInventors: Douglas E. Weitzel, Steven Carl Persak, Jeffrey C. Givand, Christopher Granelli
-
Publication number: 20230272056Abstract: Provided herein are anti-LAP antibodies (e.g., recombinant humanized, chimeric, and human anti-LAP antibodies) or antigen binding fragments thereof which have therapeutically beneficial properties, such as binding specifically to LAP-TGF?1 on cells but not to LAP-TGF?1 in extracellular matrix, as well as compositions including the same. Also provided are uses of these antibodies or antigen binding fragments in therapeutic applications, such as in the treatment of cancer, and diagnostic applications.Type: ApplicationFiled: April 8, 2021Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Chung-Ming Hsieh, Michelle Castor, Ming-Tang Chen, Alan C. Cheng, Scott A. Hollingsworth, Veronica M. Juan, Madhura Shidhore, Song Yang, Renee C.T. Moore
-
Publication number: 20230270850Abstract: The present disclosure provides, among other things, a pharmaceutical composition that includes a lipid nanoparticle adjuvant and an anti-human papillomavirus (HPV) comprising HPV virus-like particles (VLPs) of at least one type of human papillomavirus (HPV) selected from the group consisting of HPV types: 6, 11, 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 55, 56, 58, 59, 66, 68, 73, and 82.Type: ApplicationFiled: March 10, 2023Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Andrew J. Bett, John P. Bilello, Amy S. Espeseth, Tong-Ming Fu, Marian E. Gindy
-
Publication number: 20230270825Abstract: The stapled peptides of the present invention, and pharmaceutically acceptable salts thereof, are co-agonists of the glucagon and GLP-1 receptors, and may be useful in the treatment, prevention and suppression of diseases mediated by the glucagon receptor and the GLP-1 receptor, including but not limited to, metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity.Type: ApplicationFiled: December 18, 2020Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Elisabetta Bianchi, Qiaolin Deng, Songnian Lin, Federica Orvieto, Anandan Palani, Antonello Pessi, Tomi K. Sawyer
-
Publication number: 20230272001Abstract: Disclosed herein are novel processes for preparing IL-2 conjugates with one or more water-soluble polymers. In one embodiment, the IL-2 conjugate comprises five poly(ethylene glycol) polymers each of which is covalently attached to the IL-2 moiety via a releasable linkage to an amino group of the IL-2 moiety.Type: ApplicationFiled: May 17, 2021Publication date: August 31, 2023Applicant: Merck Sharp & Dohme LLCInventors: Joshua Lee, Gregory F. Pirrone, Michael J. Iammarino, David J. Roush
-
Publication number: 20230265175Abstract: Provided herein are high affinity antibodies or antigen binding fragments thereof that specifically bind to human tau-pS413. Also provided are compositions, kits, methods, and uses involving such antibodies or antigen binding fragments thereof.Type: ApplicationFiled: June 23, 2021Publication date: August 24, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jeanne E. Baker, Sophie Parmentier Batteur, Ming-Tang Chen, Alan C. Cheng, Chung-Ming Hsieh, Carl Mieczkowski, Sokreine Suon
-
Publication number: 20230266320Abstract: The present invention relates to a method of detecting the presence of Cytomegalovirus and measuring antigenicity through detection and quantification of a pentameric complex by an indirect sandwich ELISA assay which ensures an appropriate concentration of this critical glycoprotein complex is present in the vaccine.Type: ApplicationFiled: November 20, 2020Publication date: August 24, 2023Applicant: Merck Sharp & Dohme LLCInventors: Cindy J. Pauley, Lawrence William Dick, Jr., Mary Lillian Shank Retzlaff, Matthew C. Troutman, Lynne Ireland Denny, Qiana M. Wilson, Kuo-Chang Yin
-
Publication number: 20230265094Abstract: Described herein are compounds of Formula (I) or a pharmaceutically acceptable salt thereof. The compounds of Formula (I) act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.Type: ApplicationFiled: June 7, 2021Publication date: August 24, 2023Applicant: Merck Sharp & Dohme LLCInventors: Jenny Lorena Rico Duque, Phieng Siliphaivanh, Xavier Fradera, Zachary G. Brill, Jing SU
-
Publication number: 20230263887Abstract: The invention relates to stable formulations of antibodies against human programmed death receptor PD-1, or antigen binding fragments thereof. In some embodiments the formulations of the invention comprise between 5-200 mg/mL anti-PD-1 antibody, or antigen binding fragment thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. In some embodiments of the methods of the invention, the formulations are administered to a subject by intravenous or subcutaneous administration.Type: ApplicationFiled: March 10, 2023Publication date: August 24, 2023Applicant: Merck Sharp & Dohme LLCInventors: Manoj K. Sharma, Wendy Benjamin, Sarita Mittal, Ashwin Basarkar, Chakravarthy Nachu Narasimhan, Ramesh S. Kashi, Mohammed Shameem, Soumendu Bhattacharya, William P. Forrest, Jr., Yogita Krishnamachari
-
Publication number: 20230257348Abstract: The present invention is directed to cyclopentapyrrole, furopyrrole and azabicycloheptane compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.Type: ApplicationFiled: August 16, 2021Publication date: August 17, 2023Applicant: Merck Sharp & Dohme LLCInventors: Stephane L. Bogen, Dane James Clausen, Michael T. Rudd, Dong Xiao, Dexi Yang
-
Publication number: 20230257371Abstract: The present invention relates to cyclic cyanoenone derivatives of Formula (I) or pharmaceutically acceptable salts or solvates thereof, wherein R1, R2, R3, R4 and m are as defined herein. The present invention also relates to pharmaceutical compositions comprising the cyclic cyanoenone derivatives of Formula (I) and to their use in therapy.Type: ApplicationFiled: July 15, 2021Publication date: August 17, 2023Applicant: Merck Sharp & Dohme LLCInventors: Michael D. Altman, David A. Canditio, Alec H. Christian, Ornella Di Pietro, Min Lu, Umar Faruk Mansoor, Katrina Marie Mennie, Andrew J. Musacchio, Anandan Palani, Michael H. Reutershan, David Matthew Shaw, Ping Lui, Stephen St-Gallay
-
Publication number: 20230256401Abstract: A blender includes a proximal section having a proximal upper housing and a proximal lower housing, a distal section having a distal upper housing and a distal lower housing, at least one intermediate section disposed between the proximal section and the distal section and coupleable thereto, each of the at least one intermediate section including an intermediate upper housing and an intermediate lower housing, a shaft extending through the proximal section, the distal section and the at least one intermediate section, and at least one blade disposed on the shaft.Type: ApplicationFiled: April 26, 2021Publication date: August 17, 2023Applicant: Merck Sharp & Dohme LLCInventors: William Blincoe, James C. DiNunzio, M. Sebastian Escotet Espinoza, Sung Woo Kim, Graciela Terife
-
Publication number: 20230250182Abstract: Provided herein are methods of treating cancer (e.g., RCC) or von-Hippel Lindau disease, which comprise administering to a human patient in need thereof: (a) a PD-1 antagonist; (b) a HIF-2? inhibitor; and (c) lenvatinib, or a pharmaceutically acceptable salt thereof. Also provided are kits containing such agents and uses of therapeutic combinations of such agents for the treatment of cancer.Type: ApplicationFiled: June 21, 2021Publication date: August 10, 2023Applicants: Merck Sharp & Dohme LLC, Eisai R&D Management Co., Ltd.Inventors: Rodolfo Fleury Perini, Elaine M. Pinheiro, Jacqueline Willemann-Rogerio